BusinessSummit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory MeetingsBy Nasdaq OMXFeb 1, 2017, 12:01 PM UTC
BusinessSummit Appoints Dr David Roblin as Chief Operating Officer and President of Research & DevelopmentBy Nasdaq OMXJan 18, 2017, 12:01 PM UTC
BusinessSummit Appoints Dr David Roblin as Chief Operating Officer and President of Research & DevelopmentBy Nasdaq OMXJan 18, 2017, 12:01 PM UTC
BusinessSummit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational ProgressBy Nasdaq OMXDec 15, 2016, 12:00 PM UTC
BusinessSummit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2016 and Operational ProgressBy Nasdaq OMXSep 8, 2016, 11:00 AM UTC
BusinessSummit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment ConferenceBy Nasdaq OMXSep 7, 2016, 11:00 AM UTC
BusinessPositive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile InfectionBy Nasdaq OMXApr 11, 2016, 11:00 AM UTC
BusinessSummit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole’s Statistical Superiority Over Vancomycin in Sustained Clinical Response was Driven by Marked Reduction in Recurrence of C. difficile InfectionBy Nasdaq OMXMar 29, 2016, 1:25 PM UTC
